SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals informs about press release

06 Mar 2026 Evaluate

Alembic Pharmaceuticals has informed that Alembic Therapeutics LLC, a step-down wholly owned subsidiary of the company, has reported its first prescription-based sale in the United States of America (US) following the commercial launch of Pivya® (pivmecillinam) tablets, an oral prescription antibiotic. The company has enclosed its press release in this regard.

The above information is a part of company’s filings submitted to BSE.

Alembic Pharma Share Price

774.30 -10.65 (-1.36%)
20-Apr-2026 12:32 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.50
Dr. Reddys Lab 1238.75
Cipla 1240.00
Zydus Lifesciences 942.95
Lupin 2336.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×